Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-17 21:15 | 2026-11-16 | MCRB | Seres Therapeutics, Inc. | Brady Kelly | Officer | OPT+S | $1.38 | 85 | $117 | 8,775 |
| 2026-11-17 21:15 | 2026-11-16 | MCRB | Seres Therapeutics, Inc. | Shaff Eric D. | Director | OPT+S | $1.38 | 287 | $396 | 12,936 |
| 2026-11-17 21:15 | 2026-11-16 | MCRB | Seres Therapeutics, Inc. | Henn Matthew R | Officer | OPT+S | $1.38 | 101 | $139 | 8,132 |
| 2026-11-17 21:15 | 2026-11-16 | MCRB | Seres Therapeutics, Inc. | DesRosier Thomas | Officer | OPT+S | $1.38 | 103 | $142 | 8,258 |
| 2026-11-17 21:30 | 2026-11-13 | CORT | CORCEPT THERAPEUTICS INC | WILSON JAMES N | Director | SELL | $72.67 | 10,000 | $726,678 | 1,044,543 |
| 2026-11-18 01:42 | 2026-11-13 | KTTA | Pasithea Therapeutics Corp. | Coastlands Capital LP | 10% owner | BUY | $0.48 | 1,667,514 | $805,910 | 5,502,549 |
| 2026-11-18 01:42 | 2026-11-16 | BOLT | Bolt Biotherapeutics, Inc. | Coastlands Capital LP | 10% owner | BUY | $5.84 | 53,094 | $309,920 | 515,510 |
| 2026-11-18 01:29 | 2026-11-16 | PTGX | Protagonist Therapeutics, Inc | MOLINA ARTURO MD | Officer | SELL | $124.65 | 2,718 | $338,799 | 81,397 |
| 2026-11-17 22:17 | 2026-11-13 | RCKT | ROCKET PHARMACEUTICALS, INC. | Shah Gaurav | Officer | SELL | $2.25 | 3,020 | $6,795 | 1,053,574 |
| 2026-11-17 22:18 | 2026-11-13 | BOLD | Boundless Bio, Inc. | TANG KEVIN | 10% owner | BUY | $2.40 | 13,812 | $33,149 | 3,049,379 |
| 2026-11-17 22:00 | 2026-11-16 | MIRM | Mirum Pharmaceuticals, Inc. | Ramasastry Saira | Director | OPT+S | $92.28 | 2,000 | $184,560 | 0 |
| 2026-11-17 22:09 | 2026-11-13 | RCKT | ROCKET PHARMACEUTICALS, INC. | Wilson Martin | Officer | SELL | $2.25 | 4,087 | $9,196 | 541,013 |
| 2026-11-17 21:48 | 2026-11-16 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $587.74 | 9,500 | $5,583,501 | 324,443 |
| 2026-11-17 21:35 | 2026-11-13 | BBOT | BridgeBio Oncology Therapeutics, Inc. | Cobo Marc | Officer | SELL | $2.37 | 78 | $185 | 13,734 |
| 2026-11-17 21:05 | 2026-11-13 | KURA | Kura Oncology, Inc. | WILSON TROY EDWARD | Director, Officer | BUY | $7.52 | 200,000 | $1,504,760 | 679,194 |
| 2026-11-17 21:05 | 2026-11-13 | MAIA | MAIA Biotechnology, Inc. | Vitoc Vlad | Director, Officer, 10% owner | BUY | $1.00 | 100,000 | $100,000 | 1,149,121 |
| 2026-11-17 21:07 | 2026-11-13 | MAIA | MAIA Biotechnology, Inc. | Smith Stan | Director | BUY | $1.00 | 100,000 | $100,000 | 1,619,178 |
| 2026-11-17 21:07 | 2026-11-13 | PEPG | PepGen Inc. | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | BUY | $5.00 | 8,625,000 | $43,125,000 | 27,179,273 |
| 2026-11-17 13:30 | 2026-11-16 | CATX | Perspective Therapeutics, Inc. | Morich Frank | Director | BUY | $0.94 | 15,000 | $14,046 | 30,000 |
| 2026-11-17 11:30 | 2026-11-16 | RNXT | RenovoRx, Inc. | Agah Ramtin | Director, Officer | BUY | $0.93 | 50,000 | $46,485 | 848,460 |
| 2026-11-16 21:16 | 2026-11-12 | LGND | LIGAND PHARMACEUTICALS INC | Zimmermann Martine | Director | SELL | $318.17 | 2,000 | $636,336 | 1,782 |
| 2026-11-16 21:11 | 2026-11-13 | DYN | Dyne Therapeutics, Inc. | Friedl-Naderer Johanna | Officer | SELL | $16.82 | 231 | $3,885 | 152,666 |
| 2026-11-16 21:09 | 2026-11-13 | DYN | Dyne Therapeutics, Inc. | Kerr Douglas | Officer | SELL | $16.82 | 2,604 | $43,799 | 167,960 |
| 2026-11-16 21:10 | 2026-11-12 | LEGN | Legend Biotech Corp | Salovey Peter | Director | BUY | $9.16 | 20,000 | $183,250 | 75,096 |
| 2026-11-16 21:10 | 2026-11-12 | KROS | Keros Therapeutics, Inc. | Prener Anne | Director | SELL | $9.79 | 574 | $5,619 | 13,212 |
| 2026-11-16 21:07 | 2026-11-13 | IMRX | Immuneering Corp | Gengos Andrew | Officer | BUY | $3.58 | 25,000 | $89,500 | 250,000 |
| 2026-11-16 21:07 | 2026-11-13 | DYN | Dyne Therapeutics, Inc. | Cox John | Director, Officer | SELL | $16.82 | 5,513 | $92,729 | 351,994 |
| 2026-11-16 21:19 | 2026-11-12 | MRK | Merck & Co., Inc. | DeLuca Richard R. | Officer | OPT+S | $148.01 | 58,185 | $8,611,875 | 112,955 |
| 2026-11-16 22:33 | 2026-11-16 | LRMR | Larimar Therapeutics, Inc. | SHERMAN JEFFREY W | Director | BUY | $3.06 | 3,289 | $10,058 | 8,289 |
| 2026-11-16 21:19 | 2026-11-04 | CVSI | CV Sciences, Inc. | CHEEVER CHARLIE E III | 10% owner | BUY | $0.01 | 5,440,926 | $54,409 | 32,089,637 |
| 2026-11-16 22:33 | 2026-11-12 | ALDX | Aldeyra Therapeutics, Inc. | DEPTULA-HICKS DARLENE M | Director | BUY | $0.65 | 7,500 | $4,875 | 7,500 |
| 2026-11-17 00:45 | 2026-11-13 | KURA | Kura Oncology, Inc. | WILSON TROY EDWARD | Director, Officer | BUY | $7.52 | 200,000 | $1,504,760 | 635,456 |
| 2026-11-17 00:13 | 2026-11-12 | BLTE | BELITE BIO, INC | Scholl Hendrik Peter | Officer | SELL | $165.99 | 2,000 | $331,976 | 12,500 |
| 2026-11-17 00:00 | 2026-11-12 | SEPN | Septerna, Inc. | Finer Jeffrey | Director, Officer | OPT+S | $43.62 | 18,500 | $807,014 | 833,909 |
| 2026-11-16 23:44 | 2026-11-16 | ORKA | Oruka Therapeutics, Inc. | Goncalves Joana | Officer | OPT+S | $100.96 | 7,000 | $706,700 | 31,771 |
| 2026-11-16 21:35 | 2026-11-13 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $592.42 | 9,500 | $5,627,991 | 324,443 |
| 2026-11-16 21:24 | 2026-11-12 | LGND | LIGAND PHARMACEUTICALS INC | KOZARICH JOHN W | Director | SELL | $325.00 | 500 | $162,500 | 42,122 |
| 2026-11-16 21:25 | 2026-11-13 | AUPH | Aurinia Pharmaceuticals Inc. | Robertson Stephen P. | Officer | SELL | $15.97 | 11,867 | $189,516 | 576,981 |
| 2026-11-16 21:30 | 2026-11-13 | GERN | GERON CORP | Semerjian Harout | Director, Officer | BUY | $0.95 | 53,500 | $50,825 | 53,500 |
| 2026-11-16 21:30 | 2026-11-16 | GERN | GERON CORP | Williams Timothy | Officer | BUY | $0.94 | 12,000 | $11,280 | 12,000 |
| 2026-11-16 21:30 | 2026-11-13 | BIVI | BIOVIE INC. | DO CUONG V | Director, Officer | BUY | $1.16 | 2,500 | $2,906 | 18,617 |
| 2026-11-16 21:31 | 2026-11-12 | VRTX | VERTEX PHARMACEUTICALS INC / MA | WAGNER CHARLES F JR | Officer | SELL | $547.87 | 15,286 | $8,374,741 | 31,764 |
| 2026-11-16 21:00 | 2026-11-12 | AQST | Aquestive Therapeutics, Inc. | Davis Matthew W. | Officer | SELL | $3.55 | 7,197 | $25,526 | 87,500 |
| 2026-11-16 21:05 | 2026-11-12 | LFVN | Lifevantage Corp | BEINDORFF MICHAEL A | Director | SELL | $4.89 | 10,000 | $48,861 | 31,625 |
| 2026-11-16 21:05 | 2026-11-13 | DYN | Dyne Therapeutics, Inc. | Lucera Erick | Officer | SELL | $16.82 | 1,991 | $33,489 | 117,775 |
| 2026-11-16 15:30 | 2026-11-12 | PHIO | Phio Pharmaceuticals Corp. | Deming David H | Director | BUY | $0.82 | 12,000 | $9,823 | 61,800 |
| 2026-11-16 14:45 | 2026-11-12 | CTTH | CTT PHARMACEUTICAL HOLDINGS, INC. | CTT PHARMACEUTICAL HOLDINGS, INC. | Director, Officer | BUY | $0.05 | 1,500 | $81 | 9,454,036 |
| 2026-11-16 13:30 | 2026-11-12 | CATX | Perspective Therapeutics, Inc. | Woods Lori A | Director | BUY | $0.84 | 23,750 | $20,040 | 28,557 |
| 2026-11-16 13:30 | 2026-11-12 | CATX | Perspective Therapeutics, Inc. | Williamson Robert F III | Director | BUY | $0.84 | 24,898 | $20,904 | 115,271 |
| 2026-11-16 13:30 | 2026-11-12 | CATX | Perspective Therapeutics, Inc. | Morich Frank | Director | BUY | $1.00 | 15,000 | $14,957 | 15,000 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.